{
  "pmcid": "10263203",
  "sha256": "0be4b2157ba92ab7cf62b0889412766b7becd7b4f2235b9c2df761519e00d02b",
  "timestamp_utc": "2025-11-09T23:04:41.727766+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.37246031746032,
    "reading_ease": 39.3989285714286,
    "word_count": 252
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of VTE Prophylaxis and Persistent Wound Drainage After Arthroplasty"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Two hospitals were randomized to administer aspirin (100 mg daily) or enoxaparin (40 mg daily)"
      },
      "Participants": {
        "score": 2,
        "evidence": "Between April 2019 and December 2020, 1339 of 1679 eligible patients were included"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Two hospitals were randomized to administer aspirin (100 mg daily) or enoxaparin (40 mg daily)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates the association between VTE prophylaxis type (enoxaparin vs. aspirin) and persistent wound drainage."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Persistent wound drainage was defined as drainage beyond Postoperative Day 3."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomization was by hospital"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Assessors were not blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between April 2019 and December 2020, 1339 of 1679 eligible patients were included"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "1339 of 1679 eligible patients were included"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "No significant difference in persistent wound drainage was found between enoxaparin (9%) and aspirin (8%) groups (OR 1.2, 95% CI 0.8 to 1.8; p = 0.40)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source]."
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}